# PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

> **NCT00115765** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 1053 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Oxaliplatin Based Chemotherapy
- **DRUG:** Panitumumab
- **DRUG:** Irinotecan Based Chemotherapy
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00115765
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-01
- **Primary completion:** 2007-05-31
- **Final completion:** 2009-05-01
- **Target enrollment:** 1053 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115765, "PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00115765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*